Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer

Abstract

What is known and objective: Patients with ovarian cancer have not benefited substantially from immunotherapy. We report a case of ovarian cancer, however, that responded well to the programmed cell death-ligand 1 inhibitor atezolizumab.